AIM
AIM ImmunoTech Inc.
$0.5200
0.00%
$8.6M
No data for this timeframe.
Vol
Market Cap$8.6M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders3 funds
Inst. Value$20.8K
Inst. Activity2 buys / 1 sells
Reddit Sentiment71° Bullish
SEC Reports9
Press Releases8
Exchange NYSE·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0000946644·Prev Close $0.5200
Recent Activity
Jun 9, 2026
offering
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
<p align="left">OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- <strong><u>AIM ImmunoTech Inc</u></
Jun 4, 2026
SEC
AIM ImmunoTech released a video presentation and investor slide deck discussing previously published preclinical data on
8-K — Impact 3/10
May 27, 2026
Event
Kellie Wilson v. AIM Specialty Health
Court ruling from Court of Appeals for the Seventh Circuit. Docket: 23-3418
May 21, 2026
SEC
AIM ImmunoTech entered into a securities purchase agreement and placement agency agreement for a combined registered dir
8-K — Impact 8/10
May 21, 2026
SEC
AIM ImmunoTech is pricing a ~$2.44M best-efforts public offering of 7,519,351 shares at $0.325/share (20.7% discount to
424B5 — Impact 7/10
Mar 12, 2026
Insider
CHEMEROW DAVID I. sold 25 shares
Director @ $0.00 ($0.00)
Mar 12, 2026
Insider
CHEMEROW DAVID I. sold 25,000 shares
Director @ $0.00 ($0.00)
Mar 12, 2026
Insider
Equels Thomas K sold 25,000 shares
CEO & President @ $0.00 ($0.00)
Price Targets
$5.25
+1202.7% upside
Strong Buy
Current $0.4030
Low $1.50
Median $5.25
High $9.00
2 analysts
$1.50
$9.00
Analyst Ratings
1Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 1, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Apr 10, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.12 ▲ +67.6% | $-0.12 — $-0.12 | 97% YoY | 1 |
| Next Q | $-0.12 ▲ +67.6% | $-0.12 — $-0.12 | 92% YoY | 1 |
| Current FY | $-0.63 ▲ +57.1% | $-0.63 — $-0.63 | 93% YoY | 1 |
| Next FY | $-0.52 ▲ +64.6% | $-0.52 — $-0.52 | 17% YoY | 1 |
Latest Reports
BULLISH
Press
5/10
AIM ImmunoTech announced completion of enrollment in the Phase 2 DURIPANC study combining Ampligen with Imfinzi for meta
Jun 8, 2026
NEUTRAL
8-K
3/10
AIM ImmunoTech released a video presentation and investor slide deck discussing previously published preclinical data on
Jun 4, 2026
BEARISH
8-K
8/10
AIM ImmunoTech entered into a securities purchase agreement and placement agency agreement for a combined registered dir
May 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $19.8K | NEW |
| MORGAN STANLEY | $976.00 | — |
| BANK OF AMERICA CORP | $32.00 | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 12, 2026 | CHEMEROW DAVID | C | $0.00 |
| Mar 12, 2026 | CHEMEROW DAVID | C | $0.00 |
| Mar 12, 2026 | Equels Thomas | C | $0.00 |
| Mar 12, 2026 | Equels Thomas | C | $0.00 |
| Mar 6, 2026 | Equels Thomas | J | $625.0K |
Reddit Sentiment
71°
Bullish
Bearish
Neutral
Bullish
3 institutional holders with $20.8K total value (18,394 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 17,502 | $19.8K | 95.2% | NEW |
| 2 | MORGAN STANLEY | 864 | $976.00 | 4.7% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 28 | $32.00 | 0.2% | DOUBLED +440.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | NEW | — | 17,502 | — | $48.0K | 2025-Q3 |
| UBS Group AG | TRIM | 1,181 | 304 | -74.3% | $833.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 5 | 27 | +440.0% | $74.00 | 2025-Q3 |
| UBS Group AG | NEW | — | 1,181 | — | $10.2K | 2025-Q2 |
2 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 12, 2026 | CHEMEROW DAVID I. | Director | C | 25 | $0.00 | $0.00 |
| Mar 12, 2026 | CHEMEROW DAVID I. | Director | C | 25,000 | $0.00 | $0.00 |
| Mar 12, 2026 | Equels Thomas K | CEO & President | C | 25,000 | $0.00 | $0.00 |
| Mar 12, 2026 | Equels Thomas K | CEO & President | C | 25 | $0.00 | $0.00 |
| Mar 6, 2026 | Equels Thomas K | CEO & President | J | 25 | $25,000.00 | $625.0K |
| Mar 6, 2026 | Equels Thomas K | CEO & President | J | 50,000 | $0.00 | $0.00 |
| Mar 6, 2026 | CHEMEROW DAVID I. | Director | J | 25 | $25,000.00 | $625.0K |
| Mar 6, 2026 | CHEMEROW DAVID I. | Director | J | 50,000 | $0.00 | $0.00 |
| Feb 5, 2026 | CHEMEROW DAVID I. | Director | A | 2,800 | $1.23 | $3.4K |
9 SEC filing reports analyzed. Sentiment: 1 bullish, 5 bearish, 2 mixed, 1 neutral. Avg impact: 6.0/10.
NEUTRAL
8-K
3/10
AIM ImmunoTech released a video presentation and investor slide deck discussing previously published
Jun 4, 2026
BEARISH
8-K
8/10
AIM ImmunoTech entered into a securities purchase agreement and placement agency agreement for a com
May 21, 2026
BEARISH
424B5
7/10
AIM ImmunoTech is pricing a ~$2.44M best-efforts public offering of 7,519,351 shares at $0.325/share
May 21, 2026
MIXED
424B5
5/10
AIM ImmunoTech filed a 424B5 to suspend its equity distribution agreement (ATM) with Maxim Group, ha
May 19, 2026
MIXED
8-K
6/10
AIM ImmunoTech filed an 8-K reporting a $1.68M debt extension with Streeterville Capital to June 202
May 19, 2026
BULLISH
8-K
6/10
AIM ImmunoTech posted a Virtual Investor KOL Connect segment featuring Prof. Dr. Casper H.J. van Eij
May 14, 2026
BEARISH
8-K
7/10
AIM ImmunoTech closed a warrant exercise inducement transaction on May 8, 2026, receiving ~$3.6M in
May 12, 2026
BEARISH
8-K
6/10
AIM ImmunoTech Inc. amended its equity distribution agreement with Maxim Group LLC to remove the $3
Apr 10, 2026
BEARISH
424B5
6/10
AIM ImmunoTech Inc. amended its Form S-3 shelf registration to increase the maximum aggregate offeri
Apr 10, 2026
BULLISH
5/10
AIM ImmunoTech announced completion of enrollment in the Phase 2 DURIPANC study combining Ampligen w
Jun 8, 2026
NEUTRAL
4/10
AIM ImmunoTech announced ahead-of-schedule enrollment completion for its Phase 2 DURIPANC trial (Amp
Jun 1, 2026
BEARISH
7/10
AIM ImmunoTech announced a heavily dilutive registered direct offering of 7,519,351 shares at $0.325
May 20, 2026
NEUTRAL
4/10
AIM ImmunoTech issued a press release highlighting a KOL segment discussing Ampligen for late-stage
May 14, 2026
BULLISH
6/10
AIM ImmunoTech announced positive Phase 2 data for Ampligen in recurrent ovarian cancer, showing a 5
May 7, 2026
BEARISH
7/10
AIM ImmunoTech disclosed that its 2025 audited financial statements include a going concern emphasis
Apr 13, 2026
NEUTRAL
4/10
AIM ImmunoTech Inc. closed a $1.8 million rights offering, issuing units consisting of Series G Conv
Mar 7, 2026
MIXED
6/10
AIM ImmunoTech announced an agreement with Thermo Fisher Scientific's PPD clinical research unit to
Mar 2, 2026
Current analyst consensus: Strong Buy (83% buy). Based on 6 analysts: 1 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.25 mean target
+1202.7% upside
Strong Buy (1.50)
$1.50 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $0.4030 |
| Target Low | $1.50 |
| Target Mean | $5.25 |
| Target Median | $5.25 |
| Target High | $9.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.12 | $-0.12 | $-0.12 | 96.7% | +67.6% | 1↑ 0↓ | $0.0B | -100.0% | 1 |
| Next Q 2026-09-30 |
$-0.12 | $-0.12 | $-0.12 | 92.3% | +67.6% | 1↑ 0↓ | $0.0B | -100.0% | 1 |
| Current FY 2026-12-31 |
$-0.63 | $-0.63 | $-0.63 | 92.7% | +57.1% | 1↑ 0↓ | $0.0B | -30.7% | 1 |
| Next FY 2027-12-31 |
$-0.52 | $-0.52 | $-0.52 | 17.5% | +64.6% | 0↑ 1↓ | $0.0B | -18.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.120 | |
| 7d ago | $-0.370 | +0.250 |
| 30d ago | $-0.370 | +0.250 |
| 60d ago | $-1.079 | +0.959 |
| 90d ago | $-1.079 | +0.959 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 1, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Apr 10, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| May 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Apr 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Mar 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Feb 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Jan 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
71°
Bullish
Bearish
Neutral
Bullish
25 mentions
14 bullish
2 bearish
24 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 27, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 27, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 12, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| May 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 23, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 23, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 15, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 15, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 18, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 18, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 14, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Feb 15, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 14, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Why $AIM moved +158% today
▲ 1
💬 1
⚡ 0.5
$AIM ride has begun?
▲ 1
💬 0
⚡ 0.5
Amplíen and @AIM
▲ 1
💬 0
⚡ 0.5
Active Energy Group (AEG) - Fully energised UAE Ghummud datacentre triggers shift to 58 MVA scaling strategy
▲ 1
💬 1
⚡ 0.5
19 MAY 2026 , WHAT ARE THE BIGGEST WINNERS AND WHY ?
▲ 1
💬 1
⚡ 0.5
18 MAY 2026, THE BIGGEST WINNERS TODAY AND WHY ?
▲ 1
💬 0
⚡ 0.5
18 May 2026 , what are the biggest winners and why ?
▲ 1
💬 1
⚡ 0.5
Rift Helium AIM:RIFT
▲ 1
💬 1
⚡ 0.5
Rift Helium AIM:RIFT
▲ 1
💬 1
⚡ 0.5
AI health apps are everywhere. the ones with actual revenue infrastructure underneath them are not.
▲ 1
💬 1
⚡ 0.4
Touchstar plc - AIM stock
▲ 1
💬 0
⚡ 0.5
EnSilica (🇺🇸ENSIF / 🇬🇧 ENSI): Major SpaceTech Contracts
▲ 1
💬 1
⚡ 0.5
Invinity Energy Systems: All About That BESS
▲ 27
💬 13
⚡ 0.3
Invinity Energy Systems: All About That BESS
▲ 19
💬 7
⚡ 0.1
Jun 9, 2026
offering
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
<p align="left">OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- <strong><u>AIM ImmunoTech Inc</u></strong><strong>. (NYSE American: AIM) </strong>(“A
Jun 9, 2026
short_volume
Short Volume: AIM — 59.5% short (3.4M / 5.7M)
Short: 3,390,798 | Exempt: 471,505 | TRF Vol: 5,695,583 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
fda
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint <pre>Company remains on track for a planned D
Jun 8, 2026
short_volume
Short Volume: AIM — 57.4% short (13.4M / 23.4M)
Short: 13,421,333 | Exempt: 3,183,335 | TRF Vol: 23,387,969 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: AIM — 55.2% short (1.9M / 3.4M)
Short: 1,899,233 | Exempt: 416,130 | TRF Vol: 3,442,313 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
other
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness
<p align="center"><em>Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen’s previously p
Jun 4, 2026
short_volume
Short Volume: AIM — 56.4% short (7.3M / 12.9M)
Short: 7,267,206 | Exempt: 2,046,269 | TRF Vol: 12,886,419 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: AIM — 56.7% short (6.3M / 11.2M)
Short: 6,330,532 | Exempt: 1,320,992 | TRF Vol: 11,171,969 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
fda
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target <pre>Final Subject Meets
Jun 1, 2026
short_volume
Short Volume: AIM — 57.2% short (131.1M / 229.2M)
Short: 131,090,229 | Exempt: 24,883,085 | TRF Vol: 229,228,841 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: AIM — 66.7% short (4.6M / 6.9M)
Short: 4,632,706 | Exempt: 1,450,453 | TRF Vol: 6,945,784 | Short Ratio: 66.7% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: AIM — 58.9% short (32.6M / 55.3M)
Short: 32,566,368 | Exempt: 6,290,713 | TRF Vol: 55,250,295 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
May 27, 2026
other
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
<p align="center"><em>Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mou
May 27, 2026
short_volume
Short Volume: AIM — 56.4% short (178.0M / 315.6M)
Short: 178,027,760 | Exempt: 1,380,692 | TRF Vol: 315,562,384 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
May 27, 2026
Enforcement
Kellie Wilson v. AIM Specialty Health
Court ruling from Court of Appeals for the Seventh Circuit. Docket: 23-3418
May 22, 2026
short_volume
Short Volume: AIM — 55.3% short (1.2M / 2.1M)
Short: 1,152,175 | Exempt: 260,716 | TRF Vol: 2,082,204 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
May 6, 2026
Enforcement
AIM GROUP, LLC, et al. v. BTL INDUSTRIES, INC., et al.
Court ruling from District Court, D. Massachusetts. Docket: 1:26-cv-12129